Sign in
WithdrawnPhase 2

Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Jan 2017
Ended
Dec 2023
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Omega 3 fatty acid
  • Safflower seed oil
Record updated
13 October 2022
Why it stopped
Unable to recruit participants

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Age 18-55
  • Documented/ verified TBI
  • Ability to swallow study agent within 48h of injury
  • If a sexually active female who is able to get pregnant, must be already taking birth control (prescription contraception)
  • Visual acuity/ hearing adequate for testing
  • Fluency in English or Spanish
  • Ability to provide informed consent for themselves
  • Co-enrolled in PARC-TBI protocol (IRB protocol #825783) or TRACK-TBI (IRB protocol #825503)
  • GCS 13-15

Who cannot take part

  • History of pre-existing neurologic disorder, such as dementia, uncontrolled epilepsy, multiple sclerosis, strokes, brain tumors, prior severe TBI, or other disorder that confounds interpretation neuropsychological results
  • Consumption of fish or seafood 3 or more times per week on average or regular administration of omega-3 supplements (e.g., cod liver oil, borage oil, fish oil or evening primrose oil) defined as an average of 250 mg/day of n-3 HUFAs, over the previous 3 months
  • Use of anticoagulant medications or aspirin more than once per week within the last three months
  • Enrollment in any concurrent research protocols that would interfere with participant safety or research data integrity
  • Acute ischemic heart disease or abnormal heart rhythm
  • History of abnormality in liver function
  • History or evidence of active malignancy
  • History of diabetes
  • History of pre-existing disabling Axis I psychiatric disorder, such as major depression, schizophrenia, bipolar disorder or dementia
  • Allergy to omega-3 fatty acid ethyl esters or any ingredient of the study agent
  • Known allergy to Safflower seed oil or ragweed plants
  • Allergy, hypersensitivity, or intolerance to fish oils or omega-3 fats which are found in fish
  • Unstable respiratory or hemodynamic status
  • Evidence of penetrating brain injury
  • Requirement for craniotomy or craniectomy
  • Evidence of serious infectious complications
  • Pregnancy or breast-feeding
  • Prisoners or patients in custody

Where in United States

  • Penn Presbyterian Medical CenterPhiladelphia, United States

About the trial

What the trial wants to find out

This is a Phase 2 clinical trial designed to obtain data on relationships between potentially therapeutic doses of n-3 HUFA (highly unsaturated fatty acids) and their bioactive molecular derivatives, synaptamide, 17-hydroxy-DHA, and D-series resolvins, on clinical outcomes after TBI.

The 4 groups in the trial

  • 1,000mg/day n-3 HUFATreatment being tested

    Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.

    Treatment: Omega 3 fatty acid

  • 4,000 mg/day n-3 HUFATreatment being tested

    Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.

    Treatment: Omega 3 fatty acid

  • 1 capsule safflower seed oilPlacebo, for comparison

    Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.

    Treatment: Safflower seed oil

  • 4 capsules safflower seed oilPlacebo, for comparison

    Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.

    Treatment: Safflower seed oil

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Traumatic Brain Injury Recovery With n-3 Highly Unsaturated Fatty Acids (HUFAs): A Biomarker-driven Approach
Record updated
13 October 2022